Herwig P. Moll
-
- NF-κB Signaling Pathways 7
-
- interferon and immune responses 7
-
- Cytokine Signaling Pathways and Interactions 8
-
- RNA regulation and disease 3
-
- Lung Cancer Treatments and Mutations 5
-
- Virus-based gene therapy research 3
-
- Cell Adhesion Molecules Research 3
-
- Monoclonal and Polyclonal Antibodies Research 3
- Co-authors
- Emilio CasanovaIris Z. UrasChristiane FerranChristine BrostjanEva CsizmadiaThomas LavoieThomas MaierRenata Padilha Guedes
- Cited by
- Cancer ResearchImmunologyOncology
- Journals
- Nucleic Acids Research (1 paper)Journal of Biological Chemistry (1 paper)The Journal of Immunology (1 paper)
- Partner nations
- AustriaUnited StatesHungary
In The Last Decade
Herwig P. Moll
31 papers receiving 631 citations
Peers
Comparison fields: 5 of 73
- Cancer Research 129
- Immunology 180
- Oncology 200
- Molecular Biology 323
- Pulmonary and Respiratory Medicine 97
Countries citing papers authored by Herwig P. Moll
This map shows the geographic impact of Herwig P. Moll's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Herwig P. Moll with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Herwig P. Moll more than expected).
Fields of papers citing papers by Herwig P. Moll
This network shows the impact of papers produced by Herwig P. Moll. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Herwig P. Moll. The network helps show where Herwig P. Moll may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Herwig P. Moll, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2025 | 0 | |
| 3 | 2022 | 6 | |
| 4 | 2022 | 16 | |
| 5 | 2022 | 3 | |
| 6 | 2021 | 9 | |
| 7 | 2021 | 13 | |
| 8 | 2019 | 5 | |
| 9 | 2016 | 7 | |
| 10 | 2015 | 37 | |
| 11 | 2015 | 4 | |
| 12 | 2014 | 20 | |
| 13 | 2014 | 50 | |
| 14 | 2014 | 7 | |
| 15 | 2013 | 5 | |
| 16 | 2012 | 25 | |
| 17 | 2010 | 49 | |
| 18 | 2010 | 57 | |
| 19 | 2010 | 2 | |
| 20 | 2008 | 14 |
About Herwig P. Moll
Herwig P. Moll is a scholar working on Immunology, Cancer Research and Immunology and Allergy, having authored 32 papers that have together received 633 indexed citations. Recurring topics across this work include Cytokine Signaling Pathways and Interactions (8 papers), interferon and immune responses (7 papers), NF-κB Signaling Pathways (7 papers), Lung Cancer Treatments and Mutations (5 papers), Virus-based gene therapy research (3 papers), RNA regulation and disease (3 papers), Cell Adhesion Molecules Research (3 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). The work is most often cited by research in Cancer Research (129 citations), Immunology (180 citations) and Oncology (200 citations). Herwig P. Moll has collaborated with scholars based in Austria, United States and Hungary. Frequent co-authors include Emilio Casanova, Iris Z. Uras, Christiane Ferran, Christine Brostjan, Eva Csizmadia, Thomas Lavoie, Thomas Maier, Renata Padilha Guedes, Averil Ma and Andy Lee. Their work appears in journals such as Nucleic Acids Research, Journal of Biological Chemistry and The Journal of Immunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.